The battle of weight loss drugs: which is better? Mounjaro versus Ozempic.

Mounjaro is the winner !

The question has been answered by a high quality trial published in the premier medical journal ( New England Journal of Medicine).

Mounjaro is the winner !

Mounjaro is the brand name of the weight loss drug called Tirzepatide.

Mounjaro has come out on the top when it was compared to the other popular weight loss drug called Ozempic.

Ozempic is the brand name of the weight loss drug called semaglutide. Wegovy is another brand name for semaglutide .

A total of 751 participants were invoked in this trial . The trial was conducted very recently between April 2023, and November 2024.

Nearly 20% of those having Mounjaro injections had lost at  least 30% of their weight but only about 7% of people having Ozempic/ Wegovy injections lost that amount of weight.

Remember- the weight loss injections are not a one time silver bullet. Most people put the weight back on when they stop the injections. 

A healthy diet remains a very important part of weight loss.

References

  1. NEJM Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. L.J. Aronne and Others. DOI: 10.1056/NEJMoa2416394 | May 11, 2025.
  2. Guardian. People who stop weight loss drugs return to original weight within year, analysis finds (Research raises questions about long-term treatment of and support for people using weight loss drugs). Anna Bawden Health and social affairs correspondent in Málaga. Wed 14 May 2025 20.00 BST

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information research only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options, which are relevant and specific to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.